Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2018.01.016 ◽

2018 ◽

Vol 78 (5) ◽

pp. 872-881.e6 ◽

Author(s):

Emma Guttman-Yassky ◽

Patrick M. Brunner ◽

Avidan U. Neumann ◽

Saakshi Khattri ◽

Ana B. Pavel ◽

...

Keyword(s):

Monoclonal Antibody ◽

Atopic Dermatitis ◽

Severe Atopic Dermatitis ◽

Efficacy And Safety ◽

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.732534768.793555539 ◽

2019 ◽

Author(s):

Carsten Flohr

Keyword(s):

Monoclonal Antibody ◽

Atopic Dermatitis ◽

Severe Atopic Dermatitis ◽

Efficacy And Safety ◽

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.732534768.793545728 ◽

2018 ◽

Author(s):

Hidehisa Saeki

Keyword(s):

Monoclonal Antibody ◽

Atopic Dermatitis ◽

Severe Atopic Dermatitis ◽

Efficacy And Safety ◽

Download Full-text

The efficacy and safety of dupilumab in Chinese patients with moderate‐to‐severe atopic dermatitis: a randomized, double‐blind, placebo‐controlled study

British Journal of Dermatology ◽

10.1111/bjd.20690 ◽

2021 ◽

Author(s):

Y. Zhao ◽

L. Wu ◽

Q. Lu ◽

X. Gao ◽

X. Zhu ◽

...

Keyword(s):

Atopic Dermatitis ◽

Chinese Patients ◽

Controlled Study ◽

Severe Atopic Dermatitis ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

10.1016/s0140-6736(20)30732-7 ◽

2020 ◽

Vol 396 (10246) ◽

pp. 255-266 ◽

Author(s):

Eric L Simpson ◽

Rodney Sinclair ◽

Seth Forman ◽

Andreas Wollenberg ◽

Roland Aschoff ◽

...

Keyword(s):

Atopic Dermatitis ◽

Severe Atopic Dermatitis ◽

Efficacy And Safety ◽

Phase 3 ◽

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of ustekinumab in Japanese patients with severe atopic dermatitis: a randomized, double-blind, placebo-controlled, phase II study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727446943.793555535 ◽

2019 ◽

Author(s):

Carsten Flohr

Keyword(s):

Atopic Dermatitis ◽

Phase Ii ◽

Phase Ii Study ◽

Japanese Patients ◽

Severe Atopic Dermatitis ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.732534767.793543516 ◽

2018 ◽

Author(s):

Hidehisa Saeki

Keyword(s):

Monoclonal Antibody ◽

Atopic Dermatitis ◽

Phase Ii ◽

Phase Ii Trial ◽

Severe Atopic Dermatitis ◽

Efficacy And Safety ◽

Topical Corticosteroids

Download Full-text

Efficacy and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 12-week, multicentre, randomized, placebo-controlled double-blind trial

British Journal of Dermatology ◽

10.1111/j.1365-2133.2011.10775.x ◽

2012 ◽

Vol 166 (4) ◽

pp. 853-860 ◽

Author(s):

R. Bissonnette ◽

Y. Poulin ◽

Y. Zhou ◽

J. Tan ◽

H.C. Hong ◽

...

Keyword(s):

Atopic Dermatitis ◽

Severe Atopic Dermatitis ◽

Double Blind Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Download Full-text

Efficacy and safety of topical delgocitinib (JTE-052), janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: A phase III, randomized, double-blind, vehicle-controlled study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2019.06.737 ◽

2019 ◽

Vol 81 (4) ◽

pp. AB199

Keyword(s):

Atopic Dermatitis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Phase Iii ◽

Controlled Study ◽

Severe Atopic Dermatitis ◽

Efficacy And Safety ◽

Japanese Adult ◽

Double Blind ◽

Janus Kinase Inhibitor

Download Full-text

Efficacy and safety of ustekinumab in Japanese patients with severe atopic dermatitis: a randomized, double-blind, placebo-controlled, phase II study

British Journal of Dermatology ◽

10.1111/bjd.15493 ◽

2017 ◽

Vol 177 (2) ◽

pp. 419-427 ◽

Author(s):

H. Saeki ◽

K. Kabashima ◽

Y. Tokura ◽

Y. Murata ◽

A. Shiraishi ◽

...

Keyword(s):

Atopic Dermatitis ◽

Phase Ii ◽

Phase Ii Study ◽

Japanese Patients ◽

Severe Atopic Dermatitis ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

▼Dupilumab for atopic dermatitis

Drug and Therapeutics Bulletin ◽

10.1136/dtb.2018.3.0599 ◽

2018 ◽

Vol 56 (3) ◽

pp. 30-33

Keyword(s):

Monoclonal Antibody ◽

Atopic Dermatitis ◽

Systemic Therapy ◽

European Medicines Agency ◽

Severe Atopic Dermatitis ◽

Efficacy And Safety ◽

Biological Drug

▼Dupilumab (Dupixent - Sanofi-Aventis Groupe), a monoclonal antibody for the treatment of moderate-to-severe atopic dermatitis in adults who require systemic therapy, was licensed by the European Medicines Agency in September 2017. It is the first biological drug approved specifically for this condition. Here, we review the evidence for its efficacy and safety and consider its place in therapy.

Download Full-text